Answers are grounded in this paper and cite their sources.
Background: Chagas disease (CD) causes high morbimortality and the available trypanocidal treatment, including benznidazole (BZ), has limited efficacy in chronic patients. Furthermore, BZ causes adverse events (AEs) that lead to treatment definitive discontinuation in circa 30% of patients. The use of repositioned drugs or drug combination may provide an effective trypanocidal treatment. Disulfiram (DF) may enhance BZ activity and decrease BZ-related AE. This study aims to assess the safety of a new combination of drugs for CD therapy, assuming BZ as the drug of choice plus DF as repositioned drug. Methods: This single-center, open-label, phase I/II clinical trial was designed to evaluate the safety of the combined use of BZ plus DF for CD therapy. Participants are adults with indeterminate form or stage A/B1 of cardiac form of chronic CD, both sexes, aged from 18 to 70 years of age. The primary outcome will be the occurrence of severe AE. The secondary outcome will be posttreatment Trypanosoma cruzi polymerase chain reaction negativization. Six groups of 9 patients will be sequentially tested. The first group will be allocated to receive BZ 100 mg/day + DF 250 mg/day for 60 days. Upon safety confirmation (<⅓ of participants with severe AE), the combination dose will be gradually increased and dispensed to 5 groups (group II: BZ 200 mg/day + DF 250 mg/day; group III: BZ 300 mg/day + DF 250 mg/day; group IV: BZ 100 mg/day + DF 500 mg/day; group V: BZ 200 mg/day + DF 500 mg/day; group VI: BZ 300 mg/day + DF 500 mg/day) for 60 days in order to determine the maximum tolerated dose. Discussion: Our hypothesis is that the drug combination will be well tolerated and allow the proposal of phase II trials in larger scale to test the efficacy of the new drug combination in CD. We expect that the studied combination will have less AEs with an efficacy similar or superior to the current treatment. This will allow the successful treatment of a greater number of patients while decreasing the treatment cost as less patients will need treatment for AEs.
No takes yet. Share an insight, caveat, or question.
Saraiva et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: